@article{10.37349/etat.2024.00251,
abstract = {Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating evidence suggests that ICI chemotherapy is inadequate in this population. Biomarkers of ICI therapy, such as programmed cell death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes (TILs), are not biomarkers in patients with EGFR mutations, and the specificity of the tumor microenvironment has been suggested as the reason for this. Combination therapy with PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors is a concern because of its severe toxicity and limited efficacy. However, early-stage NSCLC may differ from advanced-stage NSCLC. In this review, we comprehensively review the current evidence and summarize the potential of ICI therapy in patients with EGFR mutations after acquiring resistance to treatment with EGFR-tyrosine kinase inhibitors (TKIs) with no T790M mutation or whose disease has progressed on osimertinib.},
author = {Akao, Ken and Oya, Yuko and Sato, Takaya and Ikeda, Aki and Horiguchi, Tomoya and Goto, Yasuhiro and Hashimoto, Naozumi and Kondo, Masashi and Imaizumi, Kazuyoshi},
doi = {10.37349/etat.2024.00251},
journal = {Exploration of Targeted Anti-tumor Therapy},
pages = {826--840},
title = {{It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC}},
url = {https://www.explorationpub.com/Journals/etat/Article/1002251},
volume = {5},
year = {2024},
number = {4}
}